Wednesday 30 September 2026 · Edition of the day

Current editionPast editions →

The Skeptic's Daily

The day's biggest stories, taken apart. For each one: what is actually established, what is only asserted, the questions worth asking — and a plausibility score for the central claim, given everything currently known.

Stories
2
Average plausibility
72%
How to read the score
It rates how well the core claim is evidenced — not how important the story is, nor whether it is good or bad news.
RegionAllGlobalAfricaNorth AmericaSouth AmericaAsia-PacificEuropeMiddle East
TopicAllPoliticsConflict & SecurityBusinessScienceHealth
01HealthGlobal

IARC study links about 12% of new cancers worldwide to infections

The study estimates 2.3 million infection-caused cancer cases in 2024 and points to prevention through treatment or vaccines.

France 24 reports that a study from the International Agency for Research on Cancer estimates infections caused 2.3 million new cancer cases worldwide in 2024, about 12% of all new cases. The summary says such cancers could be prevented through treatment or vaccines. Its coverage includes an interview with the study's lead author, Gary Clifford.

What holds up

  • ✓The estimate is attributed to a named research agency and study, with the lead author identified.
  • ✓The summary supplies both an absolute estimate and a proportion for 2024.

What doesn't yet

  • ?The extract provides no methods, uncertainty intervals or breakdown by infection.
  • ?It does not quantify how many cases could realistically be prevented under current treatment and vaccine access.

Ask before you share

  • →Which infections and cancer types account for the largest shares?
  • →What assumptions underpin the estimates of causation and preventability?

Sources & original reporting

  1. [1]France 24 · Published 29 Sept 2026 · france24.com
02HealthGlobal

Study reports potential benefits from unapproved weight-loss drug retatrutide

Guardian coverage describes possible weight, blood sugar and inflammation benefits, but supplies few trial details.

The Guardian reports that retatrutide could reduce body weight by a quarter, improve blood sugar levels and reduce inflammation, citing what it describes as the largest study of its kind. The drug mimics three key gut hormones. The report says it has not been approved by any regulatory agency.

What holds up

  • ✓The supplied report presents the benefits as study findings or possibilities, not guaranteed outcomes.
  • ✓It explicitly states that retatrutide remains without regulatory approval.

What doesn't yet

  • ?The extract gives no sample size, comparator, treatment duration or adverse-event data.
  • ?It is unclear whether the quarter reduction represents an average, a subgroup result or another measure.

Ask before you share

  • →What were the trial design, participant characteristics and safety findings?
  • →How large were the benefits relative to the comparator, and over what period?

Sources & original reporting

  1. [1]The Guardian · Published 29 Sept 2026 · theguardian.com